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Introduction 27 
Ischemic heart disease persists as a leading cause of premature death and disability worldwide 28 
[1]. In patients with angina, the standard of care is coronary angiography performed invasively 29 
during cardiac catheterization or non-invasively by computed tomography coronary 30 
angiography [2]. These anatomical imaging tests for coronary anatomy and disease inform the 31 
diagnosis and treatment of coronary heart disease, this being a subset (endotype) of ischemic 32 
heart disease. Around 10 million coronary angiograms are performed in clinical practice 33 
worldwide each year. 34 
During the past 5 decades, research has provided pivotal new insights in the field of medicine. 35 
Key concepts have emerged from basic research in coronary physiology, unexpected outcomes 36 
from randomized controlled trials, and epidemiology studies. Whilst a comprehensive review 37 
is beyond the scope of this editorial, some pivotal developments are noteworthy. In 1974, Lance 38 
Gould and colleagues described the physiological basis of a flow-limiting coronary artery 39 
stenosis. In an experimental model of coronary artery disease (CAD), he demonstrated that the 40 
hyperemic flow response (coronary flow reserve) was markedly impaired as stenosis severity 41 
increased beyond 60 - 70% of the reference vessel diameter in contrast to flow at rest which 42 
had a narrower range and was less affected.  Coronary flow reserve, expressed as hyperemic 43 
flow / resting flow, may be measured invasively or non-invasively [2]. Relatedly, another key 44 
concept is that coronary flow reserve may be impaired in the absence of a coronary artery 45 
stenosis. This paradox is typically explained by microvascular disease, independent of stenosis 46 
severity, which becomes clinically relevant for patients given that coronary flow reserve has 47 
prognostic importance [4,5] and, potentially, may be a modifiable therapeutic target. Another 48 
key concept is myocardial fractional flow reserve (FFR), first introduced by De Bruyne and 49 
Pijls [6,7]. FFR is a pressure-derived index that is measured invasively under hyperemic 50 
conditions; when coronary resistance is minimized, the pressure-flow relationship becomes 51 
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approximately linear [6]. FFR is defined as the fraction of myocardial blood flow in a diseased 52 
coronary artery indexed to myocardial blood flow were the artery normal [6,7]. Clinical studies 53 
using FFR to assess the functional significance of ‘lesion-level’ CAD highlighted discordance 54 
between the anatomical severity of CAD, as revealed by invasive angiography [8,9] or 55 
computed tomography coronary angiography [10]. FFR-guided percutaneous coronary 56 
intervention (PCI) reduces the risk of myocardial infarction compared to patients undergoing 57 
angiography-guided management [11,12]. Accordingly, FFR and, relatedly, non-hyperemic 58 
pressure ratios, are now recommended by practice guidelines notably to guide decisions for 59 
revascularization (or not) in patients with coronary lesions of intermediate severity [2], and 60 
FFR-CT is an emerging option in the clinic [13]. 61 
Most affected patients do not have obstructive CAD, a fact that is under-recognized by 62 
clinicians, patients and other stakeholders e.g. healthcare providers and research funders. 63 
Clinical trials involving coronary artery imaging in relatively unselected patient populations, 64 
such as Scottish Computed Tomography of the HEART (SCOT-HEART) [14,15] and the 65 
Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trials [16], 66 
have informed this gap. SCOT-HEART was a clinical trial of computed tomography coronary 67 
angiography vs. standard care in 4,146 patients referred to Chest Pain Clinics in the National 68 
Health Service in Scotland. Of 1778 (44% women) patients with known or suspected angina, 69 
only 1 in 4 had obstructive CAD, and this was 3-fold more common in men than in women 70 
(347 (29.9%) of 1162 men vs. 105 (11.5%) of 911 women; p<0.001). The cause of angina in 71 
the patients with no obstructive CAD (mostly female) was not determined, however, computed 72 
tomography coronary angiography-guided management was associated with worse angina and 73 
quality of life during follow-up [15]. Examining this conundrum further, the CorMicA study 74 
[17] determined that half of patients referred for invasive coronary angiography do not have 75 
obstructive CAD and 3 in 4 of these patients have microvascular angina and/or vasospastic 76 
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angina, most of whom are female. These findings support the case for a major reappraisal of 77 
ischemic heart disease [18]. Small vessel disease may be the most common cause of ischemic 78 
heart disease and the availability and validity of relevant tests in the clinic becomes more 79 
relevant. Clearly, anatomical and functional tests have essential, complementary value in the 80 
clinic.  81 
With these points in mind, the validity of physiological measurements in vivo has crucial 82 
importance. However, in vivo validation presents a methodological challenge. Experimental 83 
models of the coronary circulation inevitably have limitations. Theoretical concepts may be 84 
proven experimentally, but is their translation to multimorbid patients routinely valid? On the 85 
other hand, clinical physiology studies in patients necessarily require carefully considered 86 
research protocols, written informed consent and assurance of patient safety especially in 87 
relation to instrumentation of the coronary arteries. A further gap relates to correlation between 88 
clinical physiology measurements in vivo and pathological validation. With these points in 89 
mind, the research by de Waard et al [19] is a welcome addition to the literature. 90 
Van Royen’s group identify a gap in the literature relating to remodeling of the coronary 91 
microcirculation in patients with CAD. There is some controversy around whether or not 92 
microvascular remodeling occurs, such that theoretical concepts relating to minimization of 93 
coronary resistance that underpins FFR have been questioned, notably in relation to 94 
microvascular dysfunction secondary to CAD. De Waard et al [19] investigated whether 95 
microcirculatory remodeling occurs downstream of CAD in the human coronary circulation. 96 
The data were gathered from clinically-indicated post-mortem examinations in the VU 97 
University Medical Center in Amsterdam. Pathology examinations were performed using 98 
cardiac tissue from 36 deceased patients who had undergone invasive coronary angiography 99 
on clinical grounds within two years prior to death. Using formalin-fixed, paraffin embedded 100 
tissue, anti-CD31 immunostaining was performed for quantification of capillary density, 101 
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smooth muscle actin alpha staining was performed for quantification of arteriolar dimensions 102 
and density, and hematoxylin & eosin staining was used for the assessment of myocardial 103 
disease. Regions of interest were identified in the epicardium and endocardium of myocardial 104 
sections. The analyses of the microvessels (vessel counts, morphology) were undertaken 105 
manually using digital microscopy and computer-based analysis. 106 
In this study, 115 coronary arteries from 55 deceased patients who had undergone coronary 107 
angiography were assessed. Of these, 29 (53%) patients had no angiographic evidence of CAD, 108 
19 (35%) had single- or two-vessel CAD and 7 (13%) had three-vessel CAD. Therefore, 53 109 
disease-free coronary arteries from 29 negative control subjects was included. Patients with 110 
percutaneous coronary intervention or coronary artery bypass graft surgery performed between 111 
the angiogram and the post-mortem examination were excluded. In the main analysis of within-112 
subject comparisons of arteries with or without atherosclerosis, 32 pairs of an unobstructed 113 
coronary artery and a coronary artery with a stenosis within the same patient (n=55) were 114 
formed. No statistically significant differences between any of the microcirculatory parameters 115 
(microvessel density or morphology) were found. The statistics included generalized 116 
estimating equations to take account for multiple testing within the same subject. In an analysis 117 
of unpaired data including 115 coronary arteries with microvascular pathology data, again, no 118 
correlations were observed between stenosis severity, microvascular parameters and 119 
arteriogenesis.  120 
De Waard et al concluded that the human coronary microcirculation distal to non-critical 121 
stenoses does not undergo structural remodeling [19]. This conclusion supports the notion that 122 
measurements of coronary resistance in vivo, and relatedly, FFR, are not confounded by 123 
microvascular remodeling. Limitations of this study include lack of in vivo data on coronary 124 
vascular function, the sample size, retrospective design, and patient selection. The lack of 125 
perfusion fixation is an inherent limitation to pathology studies of humans. In this regard, the 126 
7 
work of William Fulton using stereo-arteriography to delineate the microcirculation and innate 127 
collateral connections is particularly revealing (Figure 1). 128 
In conclusion, de Waard et al [20] provide histopathological evidence on the human coronary 129 
microcirculation, that supports the adoption of invasive and non-invasive tests of coronary 130 
vascular function in the clinic.  131 
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Highlights 202 
• Most patients with angina do not have obstructive coronary artery disease 203 
• Coronary microvascular disease is more prevalent than macrovascular disease 204 
• The microcirculation distal to non-obstructive atherosclerotic lesions does not undergo 205 
structural remodeling. 206 
• The diagnostic evaluation of coronary artery disease and the microcirculation using 207 
invasive functional tests is useful for clinical and research purposes  208 
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Figure legend 209 
A stereoarteriogram of the left and right coronary arteries from a deceased 50-year old man. 210 
The arteriogram reveals multiple non-obstructive plaques. The microcirculation is resolved 211 
revealing the sub-endocardial plexus and collateral connections. 212 
213 
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Figure  1. 214 
